Solventum Co. (NYSE:SOLV) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. trimmed its stake in shares of Solventum Co. (NYSE:SOLV - Free Report) by 23.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 45,838 shares of the company's stock after selling 14,112 shares during the quarter. Advisors Asset Management Inc.'s holdings in Solventum were worth $3,028,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SOLV. Victory Capital Management Inc. increased its position in shares of Solventum by 137.3% in the third quarter. Victory Capital Management Inc. now owns 53,589 shares of the company's stock valued at $3,736,000 after buying an additional 31,007 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in Solventum during the third quarter worth about $315,000. Natixis Advisors LLC lifted its holdings in shares of Solventum by 271.4% in the third quarter. Natixis Advisors LLC now owns 47,616 shares of the company's stock valued at $3,320,000 after purchasing an additional 34,797 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Solventum in the third quarter valued at approximately $231,000. Finally, Prospera Private Wealth LLC acquired a new stake in shares of Solventum in the third quarter valued at approximately $35,000.

Solventum Trading Down 0.9 %

Solventum stock traded down $0.68 during midday trading on Wednesday, reaching $74.25. The stock had a trading volume of 1,900,369 shares, compared to its average volume of 1,428,247. The stock has a market capitalization of $12.84 billion and a PE ratio of 27.00. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The stock's 50-day simple moving average is $75.38 and its 200 day simple moving average is $71.73. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Piper Sandler upped their target price on Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research note on Friday, February 28th. Wells Fargo & Company boosted their price target on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Mizuho raised their price objective on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. The Goldman Sachs Group upped their target price on Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. Finally, Bank of America increased their target price on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.